Hi there, Thank you for subscribing to MarketBeat Daily Ratings. We're excited to have you onboard! Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. Please take a moment to confirm your subscription by clicking the link below. You may not receive your daily ratings newsletter without confirming your subscription. Click Here to Confirm Your Subscription to MarketBeat Daily Ratings Thank you again for subscribing. We look forward to being an important part of your investing journey.
Matthew Paulson
Founder and CEO, MarketBeat.
Confirm Your Subscription to MarketBeat Daily Ratings Here
Today's Featured Content 3 Under-the-Radar Biotechs Under $5 That Could Soar 200%Written by Chris Markoch. Published 9/9/2025. 
Key Points - Hoth Therapeutics is advancing mRNA-based therapies for cancer and obesity, with analyst targets implying over 150% upside.
- Silo Pharma combines pre-clinical psychedelic therapies with an obesity drug collaboration and a unique crypto treasury strategy.
- Anixa Biosciences develops cancer immunotherapies in partnership with leading institutions, with nearly 200% analyst upside potential.
Biotechnology stocks are often the domain of speculative investors. Many of these companies operate at the clinical or pre-clinical stage, are not yet profitable, and some are even pre-revenue—meaning any payoff could be years away. At the same time, a number of these names trade as penny stocks (under $5 per share), which can draw traders seeking short-term gains based on technical signals. Celsius rose 3,600%. Carvana jumped over 3,280%. The investors who benefited didn't wait—they acted early.
Now it's your turn. Stock Wire News is releasing a new research report featuring a company with major breakout potential. It's 100% free—no strings attached—and designed to help you stay ahead of the market. Click here to claim your free report before the next move begins. For investors with patience and conviction, however, small-cap biotech stocks can offer the chance to build positions that deliver outsized long-term returns. Below are three under-the-radar biotech stocks trading under $5 that could reward patient investors with significant upside. Hoth: Pre-Clinical Cancer Research with Major Market Potential Hoth Therapeutics Inc. (NASDAQ: HOTH) is the top performer on this list, with shares up 98% in 2025. At roughly $1.50 per share, the stock still sits about 35% below its 12-month high from January. Hoth offers speculative investors exposure to two high-demand markets: oncology and weight-loss treatments. Its lead oncology candidate, HT-KIT, employs mRNA technology to target gastrointestinal stromal tumors (GIST), systemic mastocytosis, and certain leukemias. In vitro data recently showed over 80% knockdown of KIT expression—the key oncogenic driver in these aggressive cancers. Although just two of Hoth's six pipeline programs are in active clinical trials, investors are also watching HT-VA, its obesity candidate licensed exclusively from the U.S. Department of Veterans Affairs. Analysts have set a consensus price target of $4, implying roughly 150% upside from current levels. Silo Pharma: Psychedelics, Obesity Treatment and a Crypto Twist Silo Pharma Inc. (NASDAQ: SILO) has dipped 29% in 2025 but is up more than 7% over the last three months. That gain comes partly from a non-binding letter of intent to form a 50/50 joint venture with Hoth Therapeutics to develop HT-VA, giving Silo a stake in the booming obesity-treatment market, which could exceed $100 billion globally. Silo's core focus is "novel formulations of traditional and psychedelic therapeutics." The company has four pre-clinical candidates, including SP-26 for fibromyalgia and SPU-16 for multiple sclerosis. In addition, Silo recently unveiled a cryptocurrency treasury strategy, targeting Bitcoin, Ethereum, and Solana investments. The plan uses staking to generate yield while emphasizing capital preservation. Anixa: Micro-Cap Cancer Play with Strategic Partnerships Anixa Biosciences (NASDAQ: ANIX) focuses on oncology and has advanced further down the clinical path. Two of Anixa's five pipeline candidates are in Phase 1 trials. One uses CAR-T immunotherapy to treat ovarian cancer by activating patients' T cells to destroy malignant cells. The other employs vaccine technology to generate tumor-specific antigens. Each of Anixa's programs is being developed in collaboration with leading institutions, such as the Moffitt Cancer Center, the Cleveland Clinic, or the U.S. Department of Defense. Although coverage is limited, three analysts have set a consensus price target of $10, implying about 197% upside from current prices.
| 